What Dyne’s latest clinical milestone means for the stock

Dyne Therapeutics (DYN) has fully enrolled the registrational expansion cohort in its Phase 1/2 ACHIEVE trial for z-basivarsen in myotonic dystrophy type 1. This marks a key step toward upcoming data and potential U.S. regulatory filings.

This milestone sits alongside Dyne’s broader development effort around z-basivarsen. That program includes an already ongoing global confirmatory Phase 3 HARMONIA trial and plans to use multiple trial components to support potential Accelerated Approval discussions.

At a share price of US$18.19, Dyne’s stock has seen a 7 day share price return of 6.75%, while the 1 year total shareholder return of 26.23% points to stronger momentum over a longer period, even though the year to date share price return is slightly down 1.68%.

If this kind of clinical news has your attention, it could be a good moment to scan other early stage healthcare opportunities through our screener of 40 healthcare AI stocks

With Dyne still loss making, no current revenue and the stock trading at US$18.19, the key question is whether the pipeline and recent trial progress suggest further upside, or if the market is already pricing in future growth.

DCF valuation: what our fair value implies at $18.19

On Simply Wall St's numbers, Dyne is trading at $18.19 while the SWS DCF model estimates a future cash flow value of $100.78 per share. This points to a large valuation gap. That implies the current share price is around 82% below this fair value estimate, based on the latest model output.

The DCF model works by projecting Dyne’s expected future cash flows and then discounting them back to today using a required rate of return. This approach focuses on what the business might generate over time rather than near term earnings, which is useful for a company that is still loss making with no current revenue.

For a clinical stage biotech like Dyne, this kind of model is heavily influenced by assumptions around trial success, the pace of revenue build out, and eventual profitability. With revenue forecast to grow 61.5% per year and the company still expected to be unprofitable over the next three years, the SWS DCF model is effectively baking in a long runway of future cash flows that are not yet visible in reported numbers.

Result: DCF Fair value of $100.78 (UNDERVALUED)

However, the story can change quickly if key trials disappoint or if ongoing losses of US$451.707 million limit flexibility to keep funding the pipeline on current terms.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another way to look at Dyne’s valuation

Dyne’s P/B of 3.5x looks cheaper than its peer group at 6.2x, but richer than the broader US Biotechs industry at 2.3x. That split suggests there may be room for the market to reassess the stock, while also highlighting valuation risk if sentiment changes.

For a closer look at how this P/B gap fits into a wider valuation breakdown, run your eye over the See what the numbers say about this price — find out in our valuation breakdown.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Dyne Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With both encouraging potential rewards and clear risks on the table, it pays to move quickly and test the story against the numbers yourself. Start with a closer look at the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If Dyne is on your radar, do not stop here. Broaden your watchlist with fresh ideas so you are not late to the next opportunity.

• Spot potential bargains early by reviewing companies our models flag as quality opportunities through the 44 high quality undervalued stocks
• Prioritize resilience by filtering for companies highlighted in the 70 resilient stocks with low risk scores
• Get ahead of the crowd by scanning lesser known opportunities surfaced by the screener containing 20 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.